Is GTBP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GTBP. It does not provide personalized investment advice.

GTBP (GT Biopharma Inc. Common Stock) Stock Analysis - Financials

GT Biopharma Inc. Common Stock (GTBP) is a publicly traded Healthcare sector company. As of November 9, 2026, GTBP trades at $4.46 with a market cap of $7.98M and a P/E ratio of -0.97. GTBP moved +0.00% today. Year to date, GTBP is -78.36%; over the trailing twelve months it is -68.06%. Its 52-week range spans $4.21 to $96.25. Analyst consensus is buy with an average price target of $3.00. Rallies surfaces GTBP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are GTBP's key financials?

GTBP financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. GTBP recently traded at $4.46. Market cap is $7.98M. P/E ratio is -0.97. Revenue is $0.

GTBP Key Metrics

Key financial metrics for GTBP
Metric	Value
Price	$4.46
Market Cap	$7.98M
P/E Ratio	-0.97
EPS	$-6.68
Dividend Yield	0.00%
52-Week High	$96.25
52-Week Low	$4.21
Volume	22.28K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-28.35M
Gross Margin	0.00%

GTBP Analyst Consensus

1 analysts cover GTBP: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.00.

Common questions about GTBP

What are GTBP's key financials?: GTBP financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. GTBP recently traded at $4.46. Market cap is $7.98M. P/E ratio is -0.97. Revenue is $0.
Is GTBP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GTBP. It does not provide personalized investment advice.